Studies were made of inhibition by wortmannin, a fungal metabolite, of human platelet responses to various stimuli. Wortmannin at concentrations as low as 1-100 nm inhibited several receptor-agonist-induced 5-hydroxytryptamine release from platelets, without affecting agonist-induced increases in the intracellular concentration of Ca2 Phorbol 12-myristate 13-acetate (PMA), an active tumour promoter, caused 5-hydroxytryptamine release when combined with a low concentration of ionomycin, and platelet aggregation by itself; these effects of the phorbol ester were also inhibited by wortmannin as well as by staurosporine, a potent, although non-specific, protein kinase C (PKC) inhibitor, in a similar molar concentration range. The platelet responses to the receptor agonists or PMA were accompanied by increased incorporation of [32P]P1 into pleckstrin, a protein selectively expressed in platelets and other blood cells arising from haematopoietic stem cells, as a result of PKC activation in the intact cells. The pleckstrin phosphorylation was inhibited by wortmannin in ways mostly similar to those in which it inhibited the 5-hydroxytryptamine-release responses. Nevertheless, wortmannin failed to inhibit PKC activity measurable in a cell-free asay system which is highly susceptible to staurosporine. Nor did it inhibit the translocation of cytosolic PKC to membranes induced by addition of PMA to platelet cells. Thus wortmannin, which is not a direct inhibitor of PKC, could interfere with the kinase-dependent phosphorylation of pleckstrin, which may play an important role in the cellular responses to receptor stimulation.
INTRODUCTION
Wortmannin is a mycotoxin produced by Fusarium oxysporum [1] [2] [3] . Administration of this toxin was reported to produce various toxic effects in animals [2, 3] . A derivative of wortmannin was shown to interact with certain pathway(s) of signal transduction, thereby inhibiting the respiratory burst in neutrophils [4] .
As this fungal metabolite induced severe haemorrhage in animals [2, 3] , it would be possible to assume that this agent exerts effects on physiological functions of platelets. We therefore studied effects of wortmannin on human platelets, a model system for stimulus-response coupling pathways that can be expected to have general implications for other cell types [5] [6] [7] . Unexpectedly, wortmannin inhibited platelet physiological responses to receptor agonists, probably as a result of interference with the phosphorylation of a 47 kDa protein, pleckstrin, a wellknown protein kinase C (PKC) substrate expressed selectively in haematopoietic cell lineage [5, [8] [9] [10] [11] , despite its apparent failure to affect the PKC activity in a cell-free system.
MATERIALS AND METHODS

Materials
Wortmannin, staurosporine and 9,1 1-epithio-11 ,12-methanothromboxane A2 (STA2) were kindly given by Sandoz (Basel, Switzerland), Kyowa Medex (Tokyo, Japan), and Ono Pharmaceutical Co. (Osaka, Japan) respectively. The following materials were purchased from the indicated suppliers: phorbol 12-myristate 13-acetate (PMA) (Pharmacia, Stockholm, Sweden); ionomycin (Calbiochem, La Jolla, CA, U.S.A.); thrombin (Green Cross, Osaka, Japan); H-7 (Seikagaku-Kogyo, Tokyo, Japan); 
Handling of wortmannin
Stock solutions (10 mM) of wortmannin were prepared in dimethyl sulphoxide and further diluted with incubation medium just before use. The final concentration of dimethyl sulphoxide was kept at 0.01 %, which had been found to have no effect on platelet functions. Unless otherwise mentioned, the platelet suspension had been incubated with wortmannin for 5 min at 37°C before the start of stimulation of the platelets. Essentially the same effect of wortmannin on the platelet 5-hydroxytryptamine-release reaction was observed when the preincubation time was changed from 1 to 10 min (results not shown). Wortmannin by itself did not stimulate platelets; there were no detectable changes in cell shape, 5-hydroxytryptamine or lactate dehydrogenase release, intracellular Ca2+ concentration ([Ca2+]i) or protein phosphorylation during incubation of platelets with wortmannin alone (results not shown).
1 mg of glucose/ml, 10 mM-Hepes, pH 7.4) at a cell density of 3 x 108/ml. The suspension was further supplemented with 1 mmCa2+ if not specified otherwise. All experiments using intact platelet suspensions were performed at 37 'C.
Measurements of 5-hydroxytryptamine release from platelets Platelet-rich plasma was incubated with 5-hydroxy['4C]tryptamine (100 nCi/ml) at 37 'C for 45 min. The platelets were then washed twice and resuspended in Hepes-Tyrode's buffer. This 14C-labelled platelet preparation was incubated with stimulants for indicated lengths of time, and the release reaction was stopped by addition of 0.1 % glutaraldehyde to the reaction mixture, quickly followed by immersing the mixture-containing tubes in an ice-cold bath. After centrifugation at 10000 g for 40 s at 4 'C, the radioactivity in the supernatant was determined by liquid-scintillation counting. Since collagen-induced 5-hydroxytryptamine release was dependent on aggregation (results not shown), as previously described [13, 14] , the reaction was observed under conditions in which platelets were aggregated, as described below. When indicated, platelet suspension was preincubated with 500 /LM-aspirin, a cyclo-oxygenase inhibitor, for 15 100 jug of leupeptin/ml). The homogenates thus obtained were centrifuged at 100000 g for 60 min. The resulting supernatant served as the cytosolic fraction, and the pellet was dissolved in the same volume of buffer A containing I% Triton X-100 and was used as the membrane fraction. These fractions were individually applied to 1 cm x 0.5 cm columns of DEAE-cellulose DE-52 equilibrated with buffer B (20 mM-Tris/HCl, pH 7.4,2 mM-EGTA, 50 mM-2-mercaptoethanol, 10 l,g of leupeptin/ml). After washing the columns with 15 vol. of buffer B, PKC was eluted batch-wise with 1 ml portions of 0.15 M-NaCl/buffer B. The eluates (20 ,ul) were assayed for PKC activity as described above.
13HIPDBu binding to platelets
[3H]PDBu binding to whole platelets was performed as described by Hannun et al. [19] .
RESULTS
Inhibition by wortmannin of platelet responses to various stimuli Wortmannin (1 jaM) inhibited the 5-hydroxytryptamine release induced by thrombin at lower concentrations, such as 0.02 unit/ ml (Fig. la) . The inhibition by wortmannin under these conditions was dependent on the concentration of this inhibitor used (Fig. 2a) . The inhibition induced by wortmannin became smaller as the concentration of thrombin was increased above 0.02 unit/ ml, until there was essentially no inhibition of 0.2 unit/ml (Fig.  la) . Similar results were obtained with platelets pretreated with aspirin, which only slightly inhibited thrombin-induced 5-hydroxytryptamine release (results not shown).
Collagen-induced release was markedly inhibited by 1 jaMwortmannin, especially when collagen concentration was maintained at 0.5 or 1.0 jag/ml (Fig. lb) . The inhibition observed with 1.0,ug of collagen/ml was dependent on the concentration of inhibitor added ( CU~- Fig. 2 . Dose-dependent inhibition by wortmannin of 5-hydroxytryptamine release from platelets In (a), the effects of various concentrations of wortmannin on 5-hydroxytryptamine release induced by 0.02 unit of thrombin/ml (0) (15.5 %), 1 ,ug of collagen/ml (A\) ( notion that the effect of collagen on platelets is secondary to the production of thromboxane A2 initiated by phospholipase A2 activation [20, 21] , the 5-hydroxytryptamine release elicited by lower concentrations (below 2 /tg/ml) of collagen was mostly abolished by pretreatment of the cells with aspirin. But further increase in the collagen concentration up to 5 ,ag/ml resulted in marked 5-hydroxytryptamine release, even in the presence of this cyclo-oxygenase inhibitor, which was only slightly inhibited by wortmannin.
5-Hydroxytryptamine release from platelets induced by STA2, a stable analogue of thromboxane A2 [22] [23] [24] , was markedly prevented by 1 /tM-wortmannin at any concentration of the agonist employed in either the absence (Fig. Ic) or the presence (results not shown) of aspirin, which had no effect on the STA2-induced release reaction. The inhibition by wortmannin was dependent on its concentration (Fig. 2a) .
Increase in the concentration of ionomycin above 200 nm gave rise to the concentration-dependent release of 5-hydroxytryptamine (Fig. ld) . The ionomycin-induced 5-hydroxytryptamine release was never inhibited by 1 /iM-wortmannin at any concentration of the ionophore in either the absence (Fig. Id) or the presence (results not shown) of aspirin, which partly inhibited the release induced by lower concentrations of ionomycin.
Only a small fraction of 5-hydroxytryptamine in the intracellular vesicles was released from platelets by addition of PMA alone; incubation of the platelet suspension with 1 ,tM-PMA for 5 min resulted in as little as 4.9 + 0.6% 5-hydroxytryptamine release (mean+S.E.M., n = 3). This small release was markedly inhibited by wortmannin in a dose-dependent manner even when the incubation time was prolonged to 15 min (Fig. 2b) . PMAinduced 5-hydroxytryptamine release from human platelets was enhanced by the co-addition of a low concentration (100 nM) of ionomycin that did not induce the release by itself. This 5-hydroxytryptamine release by PMA plus ionomycin was also markedly inhibited by wortmannin (Fig. le) in a dose-dependent manner (Fig. 2b) . Wortmannin was as potent as staurosporine (Fig. 2b) , a powerful, although non-specific, PKC inhibitor [25] , in inhibiting the PMA-induced 5-hydroxytryptamine release.
Unexpectedly, H-7 [26] at concentrations higher than 100 /LM or sphingosine [19, 27] The effect of wortmannin on PMA-induced aggregation of platelets was also studied. PMA at concentrations above 100 nM induced marked platelet aggregation even in the absence of ionomycin (Fig. 3a) . The 100 nM-PMA-induced aggregation was inhibited dose-dependently by wortmannin as well as by staurosporine (Fig. 3b) .
Failure by wortmannin to affect agonist-induced increases in
ICa2l1
Thrombin [28, 29] and STA2 [23, 24] are agonists ofthe receptors coupled to phospholipase C activation via G-proteins in platelets. Ca2+ mobilization induced by these agonists or a Ca2+ ionophore, ionomycin, was not inhibited by 1 gM-wortmannin at all (Fig. 4) . Dibutyryl cyclic AMP (5 mM), used for comparison, inhibited
[Ca2+]i increases induced by receptor-mediated stimuli like those observed with thrombin and STA2 (Fig. 4) .
Effect of wortmannin on protein phosphorylation
It is established that when [32P]P -labelled platelets are stimulated with PMA, pleckstrin is phosphorylated through PKC activation [5, 10] . Furthermore, PMA is also known to phosphorylate a 20 kDa protein, which is the 20 kDa light chain of myosin [30] , resulting from the action of PKC [30, 31] , rather than Ca2+-calmodulin-dependent myosin light-chain kinase that is induced by thrombin or STA2 [5, 32, 33] . Whereas pleckstrin was phosphorylated in PMA-stimulated platelets in a manner dependent on the concentrations of the phorbol ester from 1 nm up to 1 /UM (Fig. Sa) , phosphorylation of the 20 kDa protein was observed only when higher concentrations (above 100 nM) of PMA were employed. If a value of 100% was assigned to the degree of pleckstrin phosphorylation in the presence of 1 ,uM-PMA, the phosphorylation of the 20-kDa protein in the presence of 1 nM-, 10 nM-, 100 nm-and 1 ,#M-PMA was calculated to be 0.1 + 0.1 %, 1.8 + 0.6%, 6.8 + 1.0% and 14.1 + 1.5% respectively (means+S.E.M., n = 3). The pleckstrin phosphorylation induced by 1 nM-PMA was inhibited by wortmannin in a concentrationdependent manner (Fig. Sb) . The degree of wortmannin-induced inhibition became rather smaller as the concentration of PMA was increased above 10 nm, until there was no inhibition at 100 nm (Fig. 5a ). Wortmannin failed to inhibit phosphorylation of the 20 kDa protein (Fig. Sa) . Staurosporine [25, 34] phosphorylation of both pleckstrin and the 20 kDa protein (Fig.  5a ) concentration-dependently (Fig. Sb) . Thrombin and STA2 phosphorylate both pleckstrin and the 20 kDa protein through the mediation of PKC and myosin lightchain kinase respectively [5, 6] . Wortmannin inhibited the phosphorylation induced by 0.02 unit of thrombin/ml (Fig. 6a) or 100 nM-STA2 (Fig. 6b) , but did not inhibit the phosphorylation caused by 0.2 unit of thrombin/ml (Fig. 6a) . These inhibitions were well correlated with the inhibitions of 5-hydroxytryptamine release induced by these receptor-mediated agonists (Figs. la and Ic). The agonist-induced phosphorylation of pleckstrin was inhibited by wortmannin more markedly than that of the 20 kDa protein (Fig. 6) .
Lack of evidence for direct inhibition of PKC activity by wortmannin
The activity of PKC partially purified from the cytosolic fraction of human platelets, as measured by phosphorylation of histone by [y-32P]ATP, was inhibited by addition of staurosporine, but not at all by wortmannin under the conditions employed (Fig. 7) .
The binding of PKC to membranes and activation of the kinase are considered to be separable events [35, 36] . Effects of wortmannin on PKC translocation in platelets were therefore studied to gain an insight into the inhibition of pleckstrin phosphorylation. The PKC activity showed an activity change in the membrane and cytosolic fractions in a 'see-saw' fashion after incubation of platelets with PMA, presumably reflecting translocation of cytosolic PKC to membranes during the activation in intact cells (Figs. 8a and 8b) . The translocation was not prevented by the pretreatment of platelets with wortmannin (Fig. 8) mean+S.E.M., n = 3).
DISCUSSION
The potent inhibitory effects of wortmannin on platelet functions in vitro seem to be consistent with the previous finding that this fungal metabolite gave rise to severe haemorrhage in animals [2, 3] , although other mechanisms could be involved in the effect in vivo. Wortmannin inhibited 5-hydroxytryptamine release induced by thrombin, STA2 or PMA, but did not inhibit the release by ionomycin (Fig. 1) . The potency of wortmannin to inhibit PMA-induced 5-hydroxytryptamine release or aggregation could be comparable with that of staurosporine (Figs. 2b and 3b) , a potent, although non-specific, PKC inhibitor [25] . These results suggest that its inhibitory effect results from its interaction with a PKC pathway; thrombin and STA2 can activate PKC after receptor-mediated stimulation of phosphoinositide turnover [5] .
Wortmannin did not inhibit [Ca2+]i transients induced by any stimulant (Fig. 4) , indicating that the site of its interaction is distal to the production of inositol trisphosphate or Ca2+ influx through plasma membranes. The inhibition by wortmannin of thrombin-induced 5-hydroxytryptamine discharge was reversed by increasing the concentration of thrombin up to 0.2 unit/ml (Fig. Ia) . Conceivably, platelet activation induced by this agonist might be complicated by the existence of a pathway that is independent of phosphoinositide hydrolysis [29, 37] and hence insensitive to wortmannin. The inhibitory effect of wortmannin on collagen-induced platelet secretion can be explained by its inhibition of the action of thromboxane A2 which is produced after collagen stimulation of platelets [20, 21] . In fact, wortmannin inhibited the 5-hydroxytryptamine release induced by STA2, an analogue of thromboxane A2 [22] (Fig. c) .
We therefore propose that phosphorylation of pleckstrin, the well-known PKC substrate in platelets [5, [8] [9] [10] [11] , plays an important role in triggering the cellular responses (e.g. 5-hydroxytryptamine release and aggregation) to various stimuli and that inhibition of the phosphorylation by wortmannin is a mechanism involved in inhibition of the cellular responses. There was a good correlation in the susceptibility to wortmannin-induced inhibition between the two parameters, i. [32, 33] . The phosphorylation of the 20 kDa protein was less sensitive to wortmannin-induced inhibition than was phosphorylation of pleckstrin (Fig. 6) .
PMA-induced phosphorylation ofpleckstrin was also inhibited by wortmannin (Fig. 5) (Fig. 3b) . A previous study with two-dimensional gel electrophoresis revealed the presence of two or three major forms of pleckstrin [9] . Another study revealed that the pattern of the PKC-catalysed platelet protein phosphorylation induced by PMA was different from that by receptor agonists [30] . It [6] .
PKC, which catalyses pleckstrin phosphorylation, could be considered to be the most probable candidate for the site where wortmannin interacts with the intracellular signalling pathway. Nevertheless, this fungal metabolite did not directly inhibit PKC activity in a cell-free conventional assay system [18] using partially purified PKC from platelet cytosol and histone as substrate, although the same assay system was highly sensitive to staurosporine (Fig. 7) . Wortmannin added to an intact-cell preparation of platelets was also ineffective on the PMA-induced cytosolic PKC translocation to the membrane that may reflect an activation state of the protein kinase (Fig. 8) . Conceivably, the fungal metabolite may interact with intact platelets, thereby inhibiting the PKC-induced phosphorylation of pleckstrin rather indirectly in such a manner that is not reflected in altered translocation of the cytosolic protein kinase. It would be possible to assume that wortmannin may produce a condition unfavourable for pleckstrin phosphorylation by PKC as a result of its interaction with the substrate protein in the intact cells.
Since the 47 kDa protein pleckstrin was discovered in platelets [8] , the function of this PKC substrate has been controversial. Suggestions have been made for identification of this protein as lipocortin [38] , inositol 1,4,5-trisphosphate 5-phosphomonoesterase [39] , pyruvate dehydrogenase ax subunit [40] or an actin regulatory protein [41] . Recently, cDNA for this protein was cloned from HL-60 cells [10] ; the protein was found to be expressed in platelets and variously differentiated leucocytes selectively, but never in non-haematopoietic cells [10, 11] . It differed distinctly from lipocortin or pyruvate dehydrogenase ac subunit [10] , and is not only expressed but also phosphorylated upon activation of PKC in leucocytes as well as in platelets [11] .
The present results obtained with human platelets are at variance, at least in part, with those reported by Beatrice et al. [4] concerning inhibition by a derivative of wortmannin of the respiratory burst in neutrophils, in which pleckstrin is also expressed. They reported that the fungal metabolite inhibited receptor-mediated, but not PMA-induced, superoxide anion production. The inhibition was not associated with any change in [Ca2+]1, suggesting similar site(s) where wortmannin interacts with the cellular signalling pathway in neutrophils and platelets. The failure of wortmannin to inhibit PMA actions in neutrophils could be related to the fact that pleckstrin is the predominant substrate of PMA-stimulated PKC in platelets, but not so in neutrophils [11] . Further study may clarify the common mechanism underlying the different effects of wortmannin observed between these haematological cells.
